Prospective studies on the detection of minimal residual disease (MRD) in acute leukemia
patients have shown that large-scale MRD studies are feasible and that clinically relevant …

The intercellular adhesion molecule (ICAM) 1 is an Ig-like cell adhesion molecule expressed
by several cell types, including leukocytes and endothelial cells. It can be induced in a cell …

A functional genomic approach, based on systematic data gathering, was used to
characterize a family of proteins containing a tri partite m otif (TRIM). A total of 37 TRIM …

IN THE LATE 1980s and early 1990s, the elucidation of the molecular basis of acute
promyelocytic leukemia (APL) emerged as a paradigm for the connection between the …

Leukemic cells from 30% of patients with acute myeloid leukemia (AML) have an activating
mutation in the FLT3 (fms-like tyrosine kinase) gene, which represents a target for drug …

It has been shown recently in China that arsenic trioxide (As 2 O 3) is a very effective
treatment for acute promyelocytic leukemia (APL). APL patients resistant to all-trans retinoic …

We describe a novel zinc finger protein, ZID (zinc finger protein with interaction domain). At
its amino terminus ZID contains a 120-amino-acid conserved motif present in a large family …

The transforming proteins of acute promyelocytic leukaemias (APL) are fusions of the
promyelocytic leukaemia (PML) and the promyelocytic leukaemia zinc-finger (PLZF) proteins …

Abstract Arsenic trioxide (As2O3) is a highly effective treatment for patients with relapsed
acute promyelocytic leukemia (APL); its role as consolidation treatment for patients in first …

Background Acute promyelocytic leukemia (APL) is associated with a hemorrhagic disorder
of unknown cause that responds to treatment with all-trans-retinoic acid. Methods We …